Guggenheim Upgrades Mersana Therapeutics to Buy, Announces $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Michael Schmidt has upgraded Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Buy and set a price target of $7.

February 29, 2024 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Michael Schmidt upgraded Mersana Therapeutics to Buy from Neutral and set a $7 price target.
Analyst upgrades typically lead to positive short-term price movements as they reflect a positive change in the analyst's view of the company's future prospects. The upgrade from Neutral to Buy suggests a strong confidence in Mersana Therapeutics' potential for growth, and the $7 price target indicates a significant upside from the current trading price. This is likely to attract investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100